Browse the evidence

Post-myocardial infarction patients with overweight/obesity and high-risk prediabetes (HbA1c 6.0-6.4%) face a 54% five-year risk of progressing to type 2 diabetes, making them the highest-priority candidates for semaglutide treatment.

If you have had a heart attack and are overweight, getting your HbA1c checked is critical. If it is between 6.0% and 6.4%, your risk of developing full-blown diabetes within five years is over 50%. For this specific group, treatment with semaglutide (2.4 mg weekly) is highly efficient at preventing diabetes, with fewer than three people needing treatment to save one from diabetes. This makes it a priority intervention for this subgroup.

Injectable dual incretin receptor agonists (tirzepatide) produce superior mean weight loss (20.1 kg) compared to GLP-1 receptor agonists (semaglutide 14.9 kg, liraglutide 8.4 kg) in adults with overweight or obesity.

If you have obesity (BMI ≥25), injectable medications like tirzepatide, semaglutide, or liraglutide are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide offers the highest weight loss, while semaglutide balances efficacy and tolerability. Liraglutide is a moderate option, potentially suitable for those who prefer daily dosing or have lower tolerance for side effects. Discuss individual factors with your provider.

Liraglutide 3 mg daily is an effective pharmacological intervention for chronic weight management, producing a mean 5.2 kg placebo-subtracted weight loss at 1 year, with generic availability potentially improving cost-effectiveness in resource-limited settings.

If you have obesity and meet the BMI criteria, ask your doctor about liraglutide. It is a daily injection that helps suppress appetite and has been shown to help people lose an average of 5.2 kg more than placebo. Generic versions may be available, making it more affordable in some regions.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces clinically significant, dose-dependent reductions in body weight, HbA1c, systolic blood pressure, and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency across trials.

Orforglipron is an oral medication that helps reduce weight, blood sugar, blood pressure, and bad cholesterol. It works by mimicking a gut hormone (GLP-1). You take one pill a day. It can cause stomach issues like nausea, but doctors can help manage this by starting with a low dose and increasing it slowly. It is designed for people with obesity or type 2 diabetes who want to avoid injections.

Triple receptor agonists (retatrutide) produce the highest magnitude of weight loss reported to date in pharmacotherapy for obesity, surpassing dual and single GLP-1 agonists.

Retatrutide is currently the most effective drug for weight loss in this class, working by targeting three hormonal pathways (GLP-1, GIP, and glucagon). It is administered once weekly. Expect significant weight loss, but also expect gastrointestinal side effects like nausea during the initial weeks, which typically subside.

Tirzepatide (10 mg and 15 mg) provides statistically superior weight reduction and waist circumference reduction compared to semaglutide (2.4 mg) and liraglutide (3 mg) in patients with obesity or overweight without type 2 diabetes.

For patients with obesity or overweight without type 2 diabetes, Tirzepatide (10mg and 15mg doses) administered once weekly, alongside lifestyle changes, achieves significantly greater weight loss and waist circumference reduction than Semaglutide (2.4mg) or Liraglutide (3mg). The safety profile is generally comparable across all three treatments.

Incretin polyagonists (dual and triple agonists) produce weight loss and metabolic improvements comparable to, or approaching, those of bariatric surgery, serving as a potent non-surgical alternative.

If you have obesity and want significant weight loss without surgery, incretin polyagonists (like tirzepatide or retatrutide) are now a viable, highly effective medical option. They work by mimicking gut hormones to reduce appetite and improve metabolism. While they require weekly injections (or soon, oral pills), they can achieve weight loss results similar to bariatric surgery. Expect some initial stomach upset, which usually fades as your body adjusts. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (semaglutide, tirzepatide) induce significant weight loss and reduce systemic inflammation through both weight-dependent mechanisms and direct anti-inflammatory effects on cytokines (TNF-α, IL-6, CRP) and gut microbiota composition.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for weight loss and reducing inflammation. They work by mimicking a gut hormone to increase satiety and slow digestion, while also directly lowering inflammatory markers. These are prescription medications requiring weekly injections, typically starting at a lower dose and titrating up to minimize side effects.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce the progression to type 2 diabetes and improve normoglycemia in prediabetic individuals, with effects partially sustained after withdrawal.

For individuals with prediabetes, GLP-1 receptor agonists like liraglutide, semaglutide, and tirzepatide are effective in preventing type 2 diabetes and restoring normal blood sugar levels. While some benefits may diminish after stopping the medication, the initial reduction in diabetes risk is significant.

Incretin-based pharmacotherapy (specifically GLP-1 and GLP-1/GIP agonists like semaglutide and tirzepatide) is effective for significant weight loss and cardiovascular risk reduction in obesity, but discontinuation leads to rapid weight regain and loss of cardiometabolic benefits, necessitating long-term or lifelong therapy.

Incretin drugs like semaglutide and tirzepatide are highly effective for weight loss and heart health, but they are not a cure. If you stop taking them, you will likely regain the weight and lose the heart benefits. Therefore, these medications should be viewed as a long-term or lifelong treatment for obesity, combined with lifestyle changes, rather than a short-term fix.

Tirzepatide at maximum tolerated dose (MTD) is more cost-effective and clinically superior to semaglutide at MTD for weight management in US adults with obesity or overweight, resulting in lower total healthcare costs, higher quality-adjusted life years (QALYs), and reduced incidence of type 2 diabetes and cardiovascular disease.

For US adults with obesity or overweight, tirzepatide at its maximum tolerated dose is a more effective and cost-saving option than semaglutide. It leads to greater weight loss, fewer cases of diabetes and heart disease, and significant long-term healthcare cost savings, making it a superior clinical and economic choice when combined with diet and exercise.

GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) are clinically effective for glycemic control and significant weight loss, with tirzepatide demonstrating superior magnitude of weight loss compared to semaglutide in head-to-head trials.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control. Tirzepatide generally produces greater weight loss than semaglutide. However, high costs and insurance restrictions (often requiring prior failure of other drugs like metformin) limit access. Discuss cardiovascular benefits if you have existing heart disease.

Tirzepatide treatment (10-15 mg once weekly) significantly improves waist-to-height ratio (WHtR) categories compared to placebo, with 54.7% of participants improving their WHtR category at 72 weeks versus 9.6% on placebo.

If you have obesity or overweight with related health complications, treatment with tirzepatide (10-15 mg weekly) combined with lifestyle changes significantly improves your waist-to-height ratio, a key marker for cardiometabolic risk, far more effectively than placebo. This suggests a substantial reduction in central adiposity.

Tirzepatide produced a mean weight loss of −7.14 kg in individuals without diabetes and −5.87 kg in individuals with type 2 diabetes (T2D).

Tirzepatide may be an effective option for weight management in both diabetic and non-diabetic obese adults.

Supplementation with Vicia faba protein hydrolysate (VFH) at a low dose of 2.4g/day significantly enhances leg strength and muscular endurance beyond resistance training alone in healthy, untrained adults.

Take 2.4g of Vicia faba protein hydrolysate daily with your first meal while doing resistance training 3 times a week. This specific supplement has been shown to improve leg strength and endurance more than training alone, even without increasing your total protein intake.

Vicia faba protein hydrolysate (VFH) supplementation significantly increases Bone Mineral Content (BMC) compared to placebo when combined with resistance training.

If you are concerned about bone health, this specific supplement taken with resistance training may help increase bone mineral content, showing a 0.7% increase over 8 weeks.

Significant weight loss achieved through intensive lifestyle interventions, low-calorie diets, metabolic surgery, or GLP-1-based medications can induce remission of type 2 diabetes, particularly in patients with short disease duration and younger age.

If you have recently been diagnosed with Type 2 diabetes, aggressive weight loss through diet, surgery, or GLP-1 medications can potentially put your diabetes into remission, allowing you to stop medication. This is most effective if you act early, lose a significant amount of weight (10-15kg+), and maintain it. Consult your doctor about remission protocols like the DiRECT study's low-calorie diet or GLP-1 therapies.

Structured physical activity of at least 150 minutes per week significantly reduces HbA1c levels in individuals with Type 2 diabetes.

Aim for at least 150 minutes of moderate aerobic exercise (like brisk walking or cycling) every week. If time is tight, try High-Intensity Interval Training (HIIT) for shorter, effective sessions. Consistency matters more than intensity for long-term glucose control.

GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors improve glycemic control, body weight, and cardiovascular risk factors in obese patients with type 2 diabetes.

If lifestyle changes alone are insufficient, medications like GLP-1 agonists (e.g., Semaglutide) or SGLT-2 inhibitors can help manage blood sugar and support weight loss. These are prescribed when lifestyle interventions fail to meet targets.

Exercise alleviates chronic pain through neuroplasticity, endorphin release, and anti-inflammatory myokine secretion.

Regular exercise changes how your brain processes pain and releases natural painkillers (endorphins) and anti-inflammatory chemicals (myokines) from your muscles, helping you tolerate pain better.

Low-glycemic index diets improve insulin sensitivity and glycemic control, primarily through weight loss and reduced postprandial glucose spikes.

Focus on choosing carbohydrates with a lower glycemic index, such as whole grains, legumes, and vegetables. This can help manage blood sugar spikes and support weight loss. Remember that overall diet quality and fiber intake are also important.

Post-bariatric recurrent weight gain (RWG) can be effectively managed with FDA-approved anti-obesity medications (AOMs) such as GLP-1 receptor agonists (liraglutide, semaglutide), phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.

If you are gaining weight back after bariatric surgery, talk to your doctor about FDA-approved anti-obesity medications. Drugs like semaglutide (Ozempic/Wegovy) or liraglutide (Saxenda) are specifically approved and shown to help with weight loss and preventing regain. They work by affecting hormones that control hunger and stomach emptying. While they involve injections and can cause nausea, they are a potent tool to avoid more complex revisional surgeries.

Post-bariatric recurrent weight gain (RWG) can be managed with other FDA-approved anti-obesity medications including phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.

If GLP-1 injections are not suitable or effective for your post-surgery weight regain, ask your doctor about other FDA-approved oral medications. Options include phentermine/topiramate, naltrexone/bupropion, and orlistat. These drugs have different mechanisms and side effect profiles, so your doctor can help you choose the best fit. They are proven to help with weight loss and managing RWG.

Focusing on carbohydrate quality (high fiber, low glycemic load) is more effective for obesity management than restricting carbohydrate quantity (low-carb diets).

Prioritize the type of carbohydrates you eat over the amount. Choose whole grains, legumes, and fruits that are high in fiber and have a low glycemic impact. This approach supports better metabolic health and weight management compared to simply cutting out carbs.